Characteristics Number (%) with Viral Suppression* Prevalence Ratio (95%CI)† p-value† CSDS Present 22/ 55 (40.0) 0.62 (0.44-0.87) 0.002 Screening score not consistent with CSDS 85/131 (64.9)     Duration of ART Less than 36 months 39/ 83 (47.0) 0.71 (0.54-0.93) 0.009 36 months or more 68/103 (66.0)     Stratified by ART Duration  ART for less than 36 months     ‡0.37  CSDS 12/ 32 (37.5) 0.7(0.47-1.2) 0.17  Screening score not consistent with CSDS 27/ 51 (52.9)     ART for 36 months or longer  CSDS 10/23 (43.5) 0.60 0.3- 0.97) 0.009 Screening score not consistent with CSDS 58/80 (72.5)     Sex Female 64/ 98 (65.3) 1.3(1.03-1.7) 0.02 Male 42/ 86 (48.8)     Adherence to ART Perfect 85/134 (63.4) 1.5( 1.1-2.1) 0.009 Less than perfect 22/ 52 (42.3)     Stratified by Adherence     †0.34 Perfect CSDS 16/29 (41.0) 0.56(0.38-0.84) <0.001 Not consistent with CSDS 69/95 (72.6)     Less than Perfect CSDS 6/16 (37.5) 0.84(0.40, 1.75) 0.64 Not consistent with CSDS 16/36 (44.4)

Table 1: Characteristics, including clinically-significant depressive symptomatology (CSDS), associated with viral suppression* in antiretroviral therapy (ART) patients: overall and stratified by ART duration and adherence. *Analysis confined to 186 patients with at least one viral load after ART initiation, †95%CI=95% Confidence Interval, †p from uncorrected Chi-square, ‡From Chi square for differing prevalence ratios by stratum

Goto home»